benefits of glp-1 receptor agonists and cardiovascular outcome trials: An update GLP-1 Receptor Agonists in Heart

Despite fasting from solid food for more than 18 hours prior to evaluation, she described feeling full. A point-of-care gastric ultrasound was performed, which revealed solid gastric contents

At the present moment, there are currently no FDA approved medications for NASH

Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis

Cost-Effectiveness Analyses: Comprehensive economic evaluations are essential to support broader adoption within public health frameworks, assessing long-term benefits in cardiovascular event reduction and complication management to inform reimbursement policies

Studies show these medications: Lower total cholesterol, LDL cholesterol, and triglyceride levels 10 Reduce small- and medium-sized LDL particles, which are particularly harmful 10 Promote cholesterol efflux from cells through increased ABCA1 expression 11 Liraglutide and taspoglutide demonstrate exceptional cholesterol-lowering effects, especially on total cholesterol and triglycerides 10

GLP-1 drugs should be prescribed thoughtfully and with close clinical follow-up